-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
-
Summary
-
Provectus Biopharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2019 to Q2 2024.
- Provectus Biopharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was -$52K, a 49.2% decline year-over-year.
- Provectus Biopharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was -$229K, a 30.1% decline year-over-year.
- Provectus Biopharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was -$201K, a 58.2% decline from 2022.
- Provectus Biopharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was -$127K, a 85.4% increase from 2021.
- Provectus Biopharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2021 was -$867K, a 49.4% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)